{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:25:30Z","timestamp":1790778330926,"version":"4.1.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11154-017-9421-4","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T10:27:52Z","timestamp":1491388072000},"page":"79-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies"],"prefix":"10.1007","volume":"18","author":[{"given":"Mariano Rodr\u00edguez","family":"Portillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Rodr\u00edguez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"9421_CR1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1172\/JCI111696","volume":"75","author":"MS LeBeoff","year":"1985","unstructured":"LeBeoff MS, et al. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest. 1985;75:49\u201357.","journal-title":"J Clin Invest"},{"key":"9421_CR2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","volume":"366","author":"EM Brown","year":"1993","unstructured":"Brown EM, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575\u201380.","journal-title":"Nature"},{"key":"9421_CR3","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1096\/fj.15-274191","volume":"29","author":"V Shilo","year":"2015","unstructured":"Shilo V, et al. Parathyroid-specific deletion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J. 2015;29:3964\u201376.","journal-title":"FASEB J"},{"key":"9421_CR4","doi-asserted-by":"crossref","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882\u20139.","journal-title":"Am J Physiol Renal Physiol."},{"key":"9421_CR5","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","volume":"23","author":"ME Rodr\u00edguez-Ortiz","year":"2012","unstructured":"Rodr\u00edguez-Ortiz ME, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012;23:1190\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1172\/JCI118038","volume":"96","author":"R Kilav","year":"1995","unstructured":"Kilav R, et al. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest. 1995;96:327\u201333.","journal-title":"J Clin Invest"},{"key":"9421_CR7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jbmr.5650110714","volume":"11","author":"Y Almad\u00e9n","year":"1996","unstructured":"Almad\u00e9n Y, et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996;11:970\u20136.","journal-title":"J Bone Miner Res"},{"key":"9421_CR8","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/ndt\/11.9.1762","volume":"11","author":"PK Nielsen","year":"1996","unstructured":"Nielsen PK, et al. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant. 1996;11:1762\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR9","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118701","volume":"97","author":"E Slatopolsky","year":"1996","unstructured":"Slatopolsky E, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996;97:2534\u201340.","journal-title":"J Clin Invest"},{"key":"9421_CR10","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1359\/jbmr.1999.14.11.1848","volume":"14","author":"JC Estepa","year":"1999","unstructured":"Estepa JC, et al. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res. 1999;14:1848\u201354.","journal-title":"J Bone Miner Res"},{"key":"9421_CR11","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1046\/j.1523-1755.1998.00221.x","volume":"54","author":"ALM De Francisco","year":"1998","unstructured":"De Francisco ALM, et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int. 1998;54:2140\u20135.","journal-title":"Kidney Int"},{"key":"9421_CR12","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1074\/jbc.273.9.5253","volume":"273","author":"E Moallem","year":"1998","unstructured":"Moallem E, et al. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253\u20139.","journal-title":"J Biol Chem"},{"key":"9421_CR13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI112714","volume":"78","author":"J Silver","year":"1986","unstructured":"Silver J, et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest. 1986;78:1296\u2013301.","journal-title":"J Clin Invest"},{"key":"9421_CR14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ki.1991.110","volume":"39","author":"M Fukagawa","year":"1991","unstructured":"Fukagawa M, et al. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int. 1991;39:874\u201381.","journal-title":"Kidney Int"},{"key":"9421_CR15","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9421_CR16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561\u20138.","journal-title":"J Clin Invest"},{"key":"9421_CR17","first-page":"275","volume":"32","author":"M Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez M, et al. FGF23 and mineral metabolism, implications in CKD-MBD. Nefrolog\u00eda. 2012;32:275\u20138.","journal-title":"Nefrolog\u00eda"},{"key":"9421_CR18","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003\u20138.","journal-title":"J Clin Invest"},{"key":"9421_CR19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1681\/ASN.2009040427","volume":"21","author":"R Canalejo","year":"2010","unstructured":"Canalejo R, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21:1125\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR20","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. 2009;297:F282\u201391.","journal-title":"Am J Physiol Renal Physiol."},{"key":"9421_CR21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N, et al. Decreased, 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436\u201343.","journal-title":"J Clin Invest"},{"key":"9421_CR22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/ki.1996.203","volume":"49","author":"S Tall\u00f3n","year":"1996","unstructured":"Tall\u00f3n S, et al. Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Kidney Int. 1996;49:1441\u20136.","journal-title":"Kidney Int"},{"key":"9421_CR23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ki.1991.314","volume":"40","author":"M Rodr\u00edguez","year":"1991","unstructured":"Rodr\u00edguez M, et al. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int. 1991;40:1055\u201362.","journal-title":"Kidney Int"},{"key":"9421_CR24","first-page":"1598","volume":"81","author":"O Kifor","year":"1996","unstructured":"Kifor O, et al. Reduced immunostaining for the extracellular Ca2+\u2212sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598\u2013606.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ki.1997.41","volume":"51","author":"J Gogusev","year":"1997","unstructured":"Gogusev J, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328\u201336.","journal-title":"Kidney Int"},{"key":"9421_CR26","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1681\/ASN.V9112067","volume":"9","author":"RS Mathias","year":"1998","unstructured":"Mathias RS, et al. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J Am Soc Nephrol. 1998;9:2067\u201374.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1046\/j.1523-1755.1999.00386.x","volume":"55","author":"AJ Brown","year":"1999","unstructured":"Brown AJ, et al. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 1999;55:1284\u201392.","journal-title":"Kidney Int"},{"key":"9421_CR28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1046\/j.1523-1755.2001.00027.x","volume":"60","author":"CS Ritter","year":"2001","unstructured":"Ritter CS, et al. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int. 2001;60:1737\u201344.","journal-title":"Kidney Int"},{"key":"9421_CR29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jcem-52-3-499","volume":"52","author":"E Bellorin-Font","year":"1981","unstructured":"Bellorin-Font E, et al. Altered adenylate cyclase kinetics in hyperfunctioning human parathyroid glands. J Clin Endocrinol Metab. 1981;52:499\u2013507.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR30","doi-asserted-by":"crossref","first-page":"30337","DOI":"10.1074\/jbc.M201804200","volume":"277","author":"Canaff","year":"2002","unstructured":"Canaff, et al. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin. D. J Biol Chem. 2002;277:30337\u201350.","journal-title":"D. J Biol Chem"},{"key":"9421_CR31","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1172\/JCI118224","volume":"96","author":"T Naveh-Many","year":"1995","unstructured":"Naveh-Many T, et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effect of calcium, phosphate, and vitamin D. J Clin Invest. 1995;96:1786\u201393.","journal-title":"J Clin Invest"},{"key":"9421_CR32","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1097\/01.ASN.0000037676.54018.CB","volume":"13","author":"B Garfia","year":"2000","unstructured":"Garfia B, et al. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol. 2000;13:2945\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR33","doi-asserted-by":"crossref","first-page":"F1197","DOI":"10.1152\/ajprenal.00529.2009","volume":"298","author":"S Ca\u00f1adillas","year":"2010","unstructured":"Ca\u00f1adillas S, et al. Upregulation of parathyroid VDR expression by extracellular calcium is mediated by ERK1\/2-MAPK signaling pathway. Am J Physiol Renal Physiol. 2010;298:F1197\u2013204.","journal-title":"Am J Physiol Renal Physiol."},{"key":"9421_CR34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/endo.143.2.8627","volume":"143","author":"MY Zhang","year":"2002","unstructured":"Zhang MY, et al. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule. Endocrinology. 2002;143:587\u201395.","journal-title":"Endocrinology"},{"key":"9421_CR35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000188591","volume":"70","author":"H Yi","year":"1995","unstructured":"Yi H, et al. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible role of phosphorus. Nephron. 1995;70:242\u20138.","journal-title":"Nephron"},{"key":"9421_CR36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0272-6386(96)90473-4","volume":"28","author":"M Denda","year":"1996","unstructured":"Denda M, et al. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28:596\u2013602.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR37","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1210\/endo.137.11.8895317","volume":"137","author":"Q Wang","year":"1996","unstructured":"Wang Q, et al. Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Endocrinology. 1996;137:4558\u201362.","journal-title":"Endocrinology"},{"issue":"Suppl 3","key":"9421_CR38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ndt\/13.suppl_3.19","volume":"13","author":"A Canalejo","year":"1998","unstructured":"Canalejo A, et al. The effect of a high phosphorus diet on the parathyroid cell cycle. Nephrol Dial Transplant. 1998;13(Suppl 3):19\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR39","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1046\/j.1523-1755.2003.00331.x","volume":"64","author":"Y Almad\u00e9n","year":"2003","unstructured":"Almad\u00e9n Y, et al. Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int. 2003;64:2311\u20137.","journal-title":"Kidney Int"},{"key":"9421_CR40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1523-1755.2001.059003855.x","volume":"59","author":"AS Dusso","year":"2001","unstructured":"Dusso AS, et al. p21 (WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001;59:855\u201365.","journal-title":"Kidney Int"},{"key":"9421_CR41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ki.1989.89","volume":"35","author":"A Szabo","year":"1989","unstructured":"Szabo A, et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989;35:1049\u201356.","journal-title":"Kidney Int"},{"key":"9421_CR42","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1210\/endo-125-2-935","volume":"125","author":"R Kremer","year":"1989","unstructured":"Kremer R, et al. Influence of calcium and 1,25-dihyddroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology. 1989;125:935\u201341.","journal-title":"Endocrinology"},{"key":"9421_CR43","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/endo.132.6.8389284","volume":"132","author":"J Russell","year":"1993","unstructured":"Russell J, et al. Interaction between calcium and 1,25-dihydroxyvitamin D3 in the regulation of preproparathyroid hormone and vitamin D receptor messenger ribonucleic acid in avian parathyroids. Endocrinology. 1993;132:2639\u201344.","journal-title":"Endocrinology"},{"key":"9421_CR44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ndt\/gfu318","volume":"30","author":"MV Arcidiacono","year":"2015","unstructured":"Arcidiacono MV, et al. Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice. Nephrol Dial Transplant. 2015;30:434\u201340.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI118061","volume":"96","author":"SR Patel","year":"1995","unstructured":"Patel SR, et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest. 1995;96:50\u20139.","journal-title":"J Clin Invest"},{"key":"9421_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1681\/ASN.V82271","volume":"8","author":"BP Sawaya","year":"1997","unstructured":"Sawaya BP, et al. Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. J Am Soc Nephrol. 1997;8:271\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR47","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1681\/ASN.V8101546","volume":"8","author":"E Fern\u00e1ndez","year":"1997","unstructured":"Fern\u00e1ndez E, et al. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol. 1997;8:1546\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR48","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson T, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272\u20139.","journal-title":"Kidney Int"},{"key":"9421_CR49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250\u20136.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR50","doi-asserted-by":"crossref","first-page":"F217","DOI":"10.1152\/ajprenal.00332.2015","volume":"310","author":"A Hassan","year":"2016","unstructured":"Hassan A, et al. The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. Am J Physiol Renal Physiol. 2016;310:F217\u201321.","journal-title":"Am J Physiol Renal Physiol"},{"key":"9421_CR51","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1006\/bbrc.2000.4226","volume":"280","author":"N Koh","year":"2001","unstructured":"Koh N, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280:1015\u201320.","journal-title":"Biochem Biophys Res Commun"},{"key":"9421_CR52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer H, et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211\u20138.","journal-title":"Kidney Int"},{"key":"9421_CR53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, et al. Depressed expression of klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232\u20138.","journal-title":"Kidney Int"},{"key":"9421_CR54","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ki.2010.260","volume":"78","author":"T Krajisnik","year":"2010","unstructured":"Krajisnik T, et al. Parathyroid klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 2010;78:1024\u201332.","journal-title":"Kidney Int"},{"key":"9421_CR55","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370\u20138.","journal-title":"Kidney Int"},{"key":"9421_CR56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156788","volume":"11","author":"C Herencia","year":"2016","unstructured":"Herencia C, et al. Procaine inhibits osteo\/Odontogenesis through Wnt\/\u03b2-catenin inactivation. PLoS One. 2016;11:e0156788.","journal-title":"PLoS One"},{"key":"9421_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2008.12.008","volume":"433","author":"L Ling","year":"2009","unstructured":"Ling L, et al. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009;433:1\u20137.","journal-title":"Gene"},{"key":"9421_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","volume":"492","author":"DG Monroe","year":"2012","unstructured":"Monroe DG, et al. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492:1\u201318.","journal-title":"Gene"},{"key":"9421_CR59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.kint.2016.01.024","volume":"90","author":"N Carrillo-L\u00f3pez","year":"2016","unstructured":"Carrillo-L\u00f3pez N, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int. 2016;90:77\u201389.","journal-title":"Kidney Int"},{"key":"9421_CR60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1210\/jc.2006-1197","volume":"92","author":"P Bj\u00f6rklund","year":"2007","unstructured":"Bj\u00f6rklund P, et al. Accumulation of nonphosphorilated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab. 2007;92:338\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040328","volume":"4","author":"P Bj\u00f6rklund","year":"2007","unstructured":"Bj\u00f6rklund P, et al. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT\/\u03b2-catening signaling. PLoS Med. 2007;4:e328.","journal-title":"PLoS Med"},{"key":"9421_CR62","doi-asserted-by":"crossref","first-page":"523246","DOI":"10.1155\/2012\/523246","volume":"2012","author":"JG Vieira","year":"2012","unstructured":"Vieira JG. PTH assays: understanding what we have and forecasting what we will have. J Osteopor. 2012;2012:523246.","journal-title":"J Osteopor"},{"key":"9421_CR63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1172\/JCI106476","volume":"50","author":"CD Arnaud","year":"1971","unstructured":"Arnaud CD, et al. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971;50:21\u201334.","journal-title":"J Clin Invest"},{"key":"9421_CR64","first-page":"3923","volume":"81","author":"JH Brossard","year":"1996","unstructured":"Brossard JH, et al. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR65","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/clinchem\/44.4.805","volume":"44","author":"R Lepage","year":"1998","unstructured":"Lepage R, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 1998;44:805\u20139.","journal-title":"Clin Chem"},{"key":"9421_CR66","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1681\/ASN.2005101136","volume":"17","author":"J Huan","year":"2006","unstructured":"Huan J, et al. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol. 2006;17:1923\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.2001.16.4.605","volume":"16","author":"P Gao","year":"2001","unstructured":"Gao P, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001;16:605\u201314.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"9421_CR68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1744-9987.2011.00926.x","volume":"15","author":"M Taniguchi","year":"2011","unstructured":"Taniguchi M, et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial. 2011;15(Suppl 1):42\u20139.","journal-title":"Ther Apher Dial"},{"key":"9421_CR69","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.metabol.2013.05.007","volume":"62","author":"MH Gannag\u00e9-Yared","year":"2013","unstructured":"Gannag\u00e9-Yared MH, et al. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients. Metabolism. 2013;62:1416\u201322.","journal-title":"Metabolism"},{"key":"9421_CR70","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","volume":"60","author":"Monier-Faugere","year":"2001","unstructured":"Monier-Faugere, et al. Improved assessment of bone turnover by the PTH-(1\u201384)\/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460\u20138.","journal-title":"Kidney Int"},{"key":"9421_CR71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2002.34519","volume":"40","author":"G Coen","year":"2002","unstructured":"Coen G, et al. PTH 1-84 and PTH \u201c7-84\u201d in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348\u201354.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR72","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1523-1755.2005.00513.x","volume":"68","author":"G Lehmann","year":"2005","unstructured":"Lehmann G, et al. Specific measurement of PTH (1-84) in various forms of renal osteodistrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206\u201314.","journal-title":"Kidney Int"},{"key":"9421_CR73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","volume":"70","author":"JC Souberbielle","year":"2006","unstructured":"Souberbielle JC, et al. Inter-method variabilidy in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345\u201350.","journal-title":"Kidney Int"},{"key":"9421_CR74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/acb.2011.011094","volume":"49","author":"A Almond","year":"2012","unstructured":"Almond A, et al. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem. 2012;49:63\u20137.","journal-title":"Ann Clin Biochem"},{"key":"9421_CR75","volume-title":"Clinical practice guideline update on diagnosis, evaluation","author":"KDIGO","year":"2016","unstructured":"KDIGO. Clinical practice guideline update on diagnosis, evaluation. Prevention and Treatment of CKD-MBD: Public Review Draft; 2016."},{"key":"9421_CR76","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single center cohort study. Nephrol Dial Transplant. 2012;27:345\u201351.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR77","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7:1130\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR78","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10:646\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30:913\u20139.","journal-title":"J Bone Miner Res"},{"key":"9421_CR80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67:559\u201366.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000452310","volume":"189","author":"T Shigematsu","year":"2017","unstructured":"Shigematsu T, et al. Preventive strategies for vascular calcification in patients with chronic kidney disease. Contrib Nephrol. 2017;189:169\u201377.","journal-title":"Contrib Nephrol"},{"key":"9421_CR82","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR83","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fern\u00e1ndez-Mart\u00edn","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00edn JL, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542\u201351.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR84","first-page":"S1","volume":"113","author":"Kidney Disease","year":"2009","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1\u2013130.","journal-title":"Kidney Int Suppl"},{"key":"9421_CR85","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","volume":"6","author":"SM Moe","year":"2011","unstructured":"Moe SM, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:257\u201364.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR86","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1053\/j.jrn.2015.05.005","volume":"25","author":"S Ando","year":"2015","unstructured":"Ando S, et al. The effect of various boiling conditions on reduction of phosphorus and protein in meat. J Ren Nutr. 2015;25:504\u20139.","journal-title":"J Ren Nutr"},{"key":"9421_CR87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000368491","volume":"40","author":"BN Bohnert","year":"2015","unstructured":"Bohnert BN, et al. Impact of phosphorus restriction and vitamin D-substitution on secondary hyperparathyroidism in a proteinuric mouse model. Kidney Blood Press Res. 2015;40:153\u201365.","journal-title":"Kidney Blood Press Res"},{"key":"9421_CR88","doi-asserted-by":"crossref","first-page":"F1376","DOI":"10.1152\/ajprenal.90737.2008","volume":"296","author":"I L\u00f3pez","year":"2009","unstructured":"L\u00f3pez I, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Renal Physiol. 2009;296:F1376\u201385.","journal-title":"Am J Physiol Renal Physiol."},{"key":"9421_CR89","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM197601222940402","volume":"294","author":"AC Alfrey","year":"1976","unstructured":"Alfrey AC, et al. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294:184\u20138.","journal-title":"N Engl J Med"},{"key":"9421_CR90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-6386(87)80058-6","volume":"9","author":"R Swartz","year":"1987","unstructured":"Swartz R, et al. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. Am J Kidney Dis. 1987;9:217\u201323.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ndt\/17.suppl_2.21","volume":"17","author":"HH Malluche","year":"2002","unstructured":"Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant. 2002;17:21\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR92","first-page":"S114","volume":"18","author":"A Fournier","year":"1986","unstructured":"Fournier A, et al. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int Suppl. 1986;18:S114\u20139.","journal-title":"Kidney Int Suppl"},{"key":"9421_CR93","first-page":"314","volume":"12","author":"G Hercz","year":"1986","unstructured":"Hercz G, et al. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab. 1986;12:314\u20139.","journal-title":"Miner Electrolyte Metab"},{"key":"9421_CR94","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","volume":"17","author":"M Emmett","year":"1991","unstructured":"Emmett M, et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17:544\u201350.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR95","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","volume":"9","author":"S Pflanz","year":"1994","unstructured":"Pflanz S, et al. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant. 1994;9:1121\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1681\/ASN.V3196","volume":"3","author":"JA Delmez","year":"1992","unstructured":"Delmez JA, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol. 1992;3:96\u2013102.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR97","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, et al. Coronary-artery calcification in young adult with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478\u201383.","journal-title":"N Engl J Med"},{"key":"9421_CR98","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","volume":"15","author":"AP Guerin","year":"2000","unstructured":"Guerin AP, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR99","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/ndt\/gfh125","volume":"19","author":"GM Chertow","year":"2004","unstructured":"Chertow GM, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1489\u201396.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR100","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1681\/ASN.2007050622","volume":"19","author":"GM London","year":"2008","unstructured":"London GM, et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19:1837\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR101","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268\u201377.","journal-title":"Lancet"},{"key":"9421_CR102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ki.1996.22","volume":"49","author":"JA Delmez","year":"1996","unstructured":"Delmez JA, et al. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49:163\u20137.","journal-title":"Kidney Int"},{"key":"9421_CR103","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.jrn.2007.08.005","volume":"17","author":"DM Spiegel","year":"2007","unstructured":"Spiegel DM, et al. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr. 2007;17:416\u201322.","journal-title":"J Ren Nutr"},{"key":"9421_CR104","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/ndt\/gft400","volume":"29","author":"ME Rodr\u00edguez-Ortiz","year":"2014","unstructured":"Rodr\u00edguez-Ortiz ME, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant. 2014;29:282\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000366124","volume":"38","author":"P Jo\u00e3o Matias","year":"2014","unstructured":"Jo\u00e3o Matias P, et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif. 2014;38:244\u201352.","journal-title":"Blood Purif"},{"key":"9421_CR106","doi-asserted-by":"crossref","first-page":"308190","DOI":"10.1155\/2015\/308190","volume":"2015","author":"AP Silva","year":"2015","unstructured":"Silva AP, et al. Low magnesium levels and FGF-23 dysregulation predict mitral valve calcification as well as intima media thickness in predialysis diabetic patients. Int J Endocrinol. 2015;2015:308190.","journal-title":"Int J Endocrinol"},{"key":"9421_CR107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","volume":"29","author":"GM Chertow","year":"1997","unstructured":"Chertow GM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatmentof hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997;29:66\u201371.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR108","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/ndt\/14.12.2907","volume":"14","author":"GM Chertow","year":"1999","unstructured":"Chertow GM, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 1999;14:2907\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio B, et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","volume":"28","author":"D Russo","year":"2015","unstructured":"Russo D, et al. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J Nephrol. 2015;28:73\u201380.","journal-title":"J Nephrol"},{"key":"9421_CR111","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"B Di Iorio","year":"2013","unstructured":"Di Iorio B, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771\u20138.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR112","doi-asserted-by":"crossref","unstructured":"Patel L et al. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11:232\u2013244. Ojo, cambiado de orden con el siguiente trabajo!","DOI":"10.2215\/CJN.06800615"},{"key":"9421_CR113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156891","volume":"11","author":"N Sekercioglu","year":"2016","unstructured":"Sekercioglu N, et al. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One. 2016;11:e0156891.","journal-title":"PLoS One"},{"key":"9421_CR114","doi-asserted-by":"crossref","unstructured":"Habbous S, et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016; (in press)","DOI":"10.1093\/ndt\/gfw312"},{"key":"9421_CR115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245\u201352.","journal-title":"Kidney Int"},{"key":"9421_CR116","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","volume":"3","author":"K Caglar","year":"2008","unstructured":"Caglar K, et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3:61\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR117","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1681\/ASN.2008060572","volume":"20","author":"R Westenfeld","year":"2009","unstructured":"Westenfeld R, et al. Fetuin-a protects agains atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20:1264\u201374.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR118","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","volume":"24","author":"P Evenepoel","year":"2009","unstructured":"Evenepoel P, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24:278\u201385.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR119","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2169\/internalmedicine.48.1817","volume":"48","author":"I Ohno","year":"2009","unstructured":"Ohno I, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med. 2009;48:415\u201320.","journal-title":"Intern Med"},{"key":"9421_CR120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/089686080702700618","volume":"27","author":"R Ramos","year":"2007","unstructured":"Ramos R, et al. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. Perit Dial. 2007;27:697\u2013701.","journal-title":"Perit Dial"},{"key":"9421_CR121","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10157-012-0640-4","volume":"16","author":"S Iimori","year":"2012","unstructured":"Iimori S, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialylzed patients: a propensity-matched observational study. Clin Exp Nephrol. 2012;16:930\u20137.","journal-title":"Clin Exp Nephrol"},{"key":"9421_CR122","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","volume":"100","author":"AJ Hutchison","year":"2005","unstructured":"Hutchison AJ, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:c8\u201319.","journal-title":"Nephron Clin Pract."},{"key":"9421_CR123","doi-asserted-by":"crossref","first-page":"c61","DOI":"10.1159\/000088932","volume":"102","author":"AJ Hutchison","year":"2006","unstructured":"Hutchison AJ, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61\u201371.","journal-title":"Nephron Clin Pract"},{"key":"9421_CR124","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1744-9987.2007.00541.x","volume":"12","author":"T Shigematsu","year":"2008","unstructured":"Shigematsu T, et al. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing dialysis. Ther Apher Dial. 2008;12:55\u201361.","journal-title":"Ther Apher Dial"},{"key":"9421_CR125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","volume":"55","author":"K Uhling","year":"2010","unstructured":"Uhling K, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773\u201399.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/j.jrn.2014.10.013","volume":"25","author":"M Inaba","year":"2015","unstructured":"Inaba M, et al. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr. 2015;25:242\u20136.","journal-title":"J Ren Nutr"},{"key":"9421_CR127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ndt\/gfu335","volume":"30","author":"H Komaba","year":"2015","unstructured":"Komaba H, et al. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant. 2015;30:107\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/1744-9987.12399","volume":"20","author":"K Tsuchida","year":"2016","unstructured":"Tsuchida K, et al. Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima study). Ther Apher Dial. 2016;20:142\u20138.","journal-title":"Ther Apher Dial"},{"key":"9421_CR129","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","volume":"65","author":"GA Block","year":"2015","unstructured":"Block GA, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis. 2015;65:728\u201336.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR130","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis JB, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26:493\u2013503.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR131","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638\u201347.","journal-title":"Kidney Int"},{"key":"9421_CR132","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/ndt\/gft064","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, et al. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphatemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant. 2013;28:1874\u201388.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR133","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000441648","volume":"41","author":"F Locatelli","year":"2016","unstructured":"Locatelli F, et al. Long-term evaluation of colestilan in chronic kidney disease stage 5 dialysis patients with hyperphosphatemia. Blood Purif. 2016;41:247\u201353.","journal-title":"Blood Purif"},{"key":"9421_CR134","doi-asserted-by":"crossref","unstructured":"Lenglet A et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 2016.","DOI":"10.1093\/ndt\/gfw042"},{"key":"9421_CR135","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2013-1294","volume":"98","author":"M Metzger","year":"2013","unstructured":"Metzger M, et al. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab. 2013;98:2922\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR136","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1681\/ASN.2009030283","volume":"20","author":"ML Melamed","year":"2009","unstructured":"Melamed ML, et al. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20:2631\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR137","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/ndt\/gfq650","volume":"26","author":"C Garc\u00eda-Cant\u00f3n","year":"2011","unstructured":"Garc\u00eda-Cant\u00f3n C, et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. 2011;26:2250\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR138","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1093\/ndt\/gfr076","volume":"26","author":"S Pilz","year":"2011","unstructured":"Pilz S, et al. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant. 2011;26:3603\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR139","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","volume":"67","author":"KP Nordal","year":"1988","unstructured":"Nordal KP, et al. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67:929\u201336.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","volume":"321","author":"DL Andress","year":"1989","unstructured":"Andress DL, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;321:274\u20139.","journal-title":"N Engl J Med"},{"key":"9421_CR141","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ki.1989.305","volume":"36","author":"R Dunlay","year":"1989","unstructured":"Dunlay R, et al. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int. 1989;36:1093\u20138.","journal-title":"Kidney Int"},{"key":"9421_CR142","first-page":"6193751","volume":"2016","author":"XX Liang","year":"2016","unstructured":"Liang XX, et al. The significance of ultrasound in determining whether SHPT patients are sensitive to calcitriol treatment. Biomed Res Int. 2016;2016:6193751.","journal-title":"Biomed Res Int"},{"key":"9421_CR143","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","volume":"34","author":"HZ Tonbul","year":"2012","unstructured":"Tonbul HZ, et al. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail. 2012;34:297\u2013303.","journal-title":"Ren Fail"},{"key":"9421_CR144","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/ndt\/gft227","volume":"28","author":"DW Coyne","year":"2013","unstructured":"Coyne DW, et al. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAl study. Nephrol Dial Transplant. 2013;28:2260\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR145","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"SM Sprague","year":"2001","unstructured":"Sprague SM, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001;38:S51\u20136.","journal-title":"Am J Kidney Dis"},{"key":"9421_CR146","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483\u201390.","journal-title":"Kidney Int"},{"key":"9421_CR147","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1744-9987.12434","volume":"20","author":"\u017d Ve\u010deri\u0107-Haler","year":"2016","unstructured":"Ve\u010deri\u0107-Haler \u017d, et al. Comparison of the pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis population. Ther Apher Dial. 2016;20:261\u20136.","journal-title":"Ther Apher Dial"},{"key":"9421_CR148","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27:3270\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR149","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.nefro.2015.06.018","volume":"35","author":"FJ Borrego Utiel","year":"2015","unstructured":"Borrego Utiel FJ, et al. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Nefrologia. 2015;35:363\u201373.","journal-title":"Nefrologia"},{"key":"9421_CR150","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/ajt.12227","volume":"13","author":"H Amer","year":"2013","unstructured":"Amer H, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13:1576\u201385.","journal-title":"Am J Transplant"},{"key":"9421_CR151","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1097\/TP.0000000000001339","volume":"100","author":"J Donate-Correa","year":"2016","unstructured":"Donate-Correa J, et al. Effect of paricalcitol on FGF-23 and klotho in kidney transplant recipients. Transplantation. 2016;100:2432\u20138.","journal-title":"Transplantation"},{"key":"9421_CR152","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11255-015-1195-6","volume":"48","author":"P Cai","year":"2016","unstructured":"Cai P, et al. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2016;48:571\u201384.","journal-title":"Int Urol Nephrol"},{"key":"9421_CR153","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000362846","volume":"39","author":"JB Zella","year":"2014","unstructured":"Zella JB, et al. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am J Nephrol. 2014;39:476\u201383.","journal-title":"Am J Nephrol"},{"key":"9421_CR154","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000445756","volume":"43","author":"R Pandey","year":"2016","unstructured":"Pandey R, et al. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2016;43:213\u201320.","journal-title":"Am J Nephrol"},{"key":"9421_CR155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1744-9987.2008.00559.x","volume":"12","author":"N Al-Hilali","year":"2008","unstructured":"Al-Hilali N, et al. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. Ther Apher Dial. 2008;12:137\u201342.","journal-title":"Ther Apher Dial"},{"key":"9421_CR156","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.bjp.0706138","volume":"144","author":"J Michaud","year":"2005","unstructured":"Michaud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005;144:1067\u201377.","journal-title":"Br J Pharmacol"},{"key":"9421_CR157","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5414\/CP202430","volume":"53","author":"S Bezzaoucha","year":"2015","unstructured":"Bezzaoucha S, et al. Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients. Int J Clin Pharmacol Ther. 2015;53:895\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9421_CR158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12882-015-0006-8","volume":"16","author":"P Messa","year":"2015","unstructured":"Messa P, et al. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol. 2015;16:11.","journal-title":"BMC Nephrol"},{"key":"9421_CR159","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000346846","volume":"37","author":"F Duranton","year":"2013","unstructured":"Duranton F, et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37:239\u201348.","journal-title":"Am J Nephrol"},{"key":"9421_CR160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/IJNRD.S90968","volume":"8","author":"A Cupisti","year":"2015","unstructured":"Cupisti A, et al. Vitamin D status and cholecalciferol supplementation in chronic kidney disease: an Italian cohort report. Int J Nephrol Renovasc Dis. 2015;8:151\u20137.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"9421_CR161","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1744-9987.12279","volume":"19","author":"JL Merino","year":"2015","unstructured":"Merino JL, et al. Effects of a single, high oral dose of 15-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients. Ther Apher Dial. 2015;19:212\u20139.","journal-title":"Ther Apher Dial"},{"key":"9421_CR162","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12882-015-0116-3","volume":"16","author":"E Zitt","year":"2015","unstructured":"Zitt E, et al. Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency. BMC Nephrol. 2015;16:128.","journal-title":"BMC Nephrol"},{"key":"9421_CR163","doi-asserted-by":"crossref","first-page":"277","DOI":"10.20452\/pamw.1768","volume":"123","author":"T Hryszko","year":"2013","unstructured":"Hryszko T, et al. Cholecalciferol supplementation reduces soluble klotho concentration in hemodialysis patients. Pol Arch Med Wewn. 2013;123:277\u201381.","journal-title":"Pol Arch Med Wewn"},{"key":"9421_CR164","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.clnu.2016.04.014","volume":"35","author":"MS Meireles","year":"2016","unstructured":"Meireles MS, et al. Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: a randomized controlled trial. Clin Nutr. 2016;35:1251\u20138.","journal-title":"Clin Nutr"},{"key":"9421_CR165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2015040468","volume":"27","author":"DC Miskulin","year":"2016","unstructured":"Miskulin DC, et al. Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial. J Am Soc Nephrol. 2016;27:1801\u201310.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR166","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000430813","volume":"130","author":"R Mangoo-Karim","year":"2015","unstructured":"Mangoo-Karim R, et al. Ergocalciferol versus cholecalciferol for nutritional vitamin D replacement in CKD. Nephron. 2015;130:99\u2013104.","journal-title":"Nephron"},{"key":"9421_CR167","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1681\/ASN.2007121320","volume":"19","author":"C Valle","year":"2008","unstructured":"Valle C, et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol. 2008;19:2430\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR168","first-page":"i12","volume":"1","author":"J Frazao","year":"2008","unstructured":"Frazao J, et al. Secondary hyperparathyroidism disease stabilization following calcimimetic therapy. NDT Plus. 2008;1:i12\u20137.","journal-title":"NDT Plus"},{"key":"9421_CR169","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","volume":"28","author":"M Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez M, et al. The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review. Semin Dial. 2015;28:497\u2013507.","journal-title":"Semin Dial"},{"key":"9421_CR170","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516\u201325.","journal-title":"N Engl J Med"},{"key":"9421_CR171","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10:e1001436.","journal-title":"PLoS Med"},{"key":"9421_CR173","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","unstructured":"EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482\u201394.","journal-title":"N Engl J Med"},{"key":"9421_CR174","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR175","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","volume":"2","author":"GM Chertow","year":"2007","unstructured":"Chertow GM, et al. Evaluation of Cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898\u2013905.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR176","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/ndt\/gfr777","volume":"27","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, et al. Baseline characteristics of subjects enrolled in the evaluation of Cinacalcet HCl therapy to lower cardiovascular (EVOLVE) trial. Nephrol Dial Transplant. 2012;27:2872\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR177","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"PS Parfrey","year":"2015","unstructured":"Parfrey PS, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR178","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","volume":"98","author":"PS Parfrey","year":"2013","unstructured":"Parfrey PS, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98:4834\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"9421_CR179","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe SM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26:1466\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"9421_CR180","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.transproceed.2012.09.049","volume":"44","author":"RP Paschoalin","year":"2012","unstructured":"Paschoalin RP, et al. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. Transplant Proc. 2012;44:2588\u20139.","journal-title":"Transplant Proc"},{"key":"9421_CR181","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nep.12186","volume":"19","author":"JV Torregrosa","year":"2014","unstructured":"Torregrosa JV, et al. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology. 2014;19:84\u201393.","journal-title":"Nephrology"},{"key":"9421_CR182","doi-asserted-by":"crossref","first-page":"292654","DOI":"10.1155\/2015\/292654","volume":"2015","author":"U Thiem","year":"2015","unstructured":"Thiem U, et al. Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation. Biomed Res Int. 2015;2015:292654.","journal-title":"Biomed Res Int"},{"key":"9421_CR183","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0b013e31826c3968","volume":"94","author":"JB Cohen","year":"2012","unstructured":"Cohen JB, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation. 2012;94:1041\u20138.","journal-title":"Transplantation"},{"key":"9421_CR184","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346:229\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"9421_CR185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2369-15-81","volume":"15","author":"S Walter","year":"2014","unstructured":"Walter S, et al. Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol. 2014;15:81.","journal-title":"BMC Nephrol"},{"key":"9421_CR186","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","volume":"29","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29:385\u201392.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR187","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85:191\u20137.","journal-title":"Kidney Int"},{"key":"9421_CR188","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, et al. A randomized, double-blind-phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31:943\u201352.","journal-title":"Curr Med Res Opin"},{"key":"9421_CR189","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ndt\/gfv050","volume":"30","author":"D Goldsmith","year":"2015","unstructured":"Goldsmith D, et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant. 2015;30:698\u2013700.","journal-title":"Nephrol Dial Transplant"},{"key":"9421_CR190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR191","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2215\/CJN.10370915","volume":"11","author":"SM Kim","year":"2016","unstructured":"Kim SM, et al. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin J Am Soc Nephrol. 2016;11:1260\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9421_CR192","volume":"11","author":"YH Hsu","year":"2016","unstructured":"Hsu YH, et al. The risk of peripheral arterial disease after parathyroidectomy in patients with end-stage renal disease. PLoS One. 2016;11:e0156863.","journal-title":"PLoS One"},{"key":"9421_CR193","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00423-011-0901-9","volume":"397","author":"B Kovacevic","year":"2012","unstructured":"Kovacevic B, et al. Parathyroidectomy for the attainment of NKF-K\/DOQI\u2122 and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism. Langenbeck's Arch Surg. 2012;397:413\u201320.","journal-title":"Langenbeck's Arch Surg"},{"key":"9421_CR194","first-page":"9830","volume":"8","author":"C Chen","year":"2015","unstructured":"Chen C, et al. Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism. Int J Clin Exp Med. 2015;8:9830\u20138.","journal-title":"Int J Clin Exp Med"},{"key":"9421_CR195","doi-asserted-by":"crossref","unstructured":"Jiang Y, et al. Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci Rep. 2016;27918","DOI":"10.1038\/srep27918"},{"key":"9421_CR196","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/0886022X.2016.1184924","volume":"38","author":"L Chen","year":"2016","unstructured":"Chen L, et al. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Ren Fail. 2016;38:1050\u20138.","journal-title":"Ren Fail"},{"key":"9421_CR197","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00423-016-1447-7","volume":"401","author":"K Konturek","year":"2016","unstructured":"Konturek K, et al. Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study. Langenbeck's Arch Surg. 2016;401:965\u201374.","journal-title":"Langenbeck's Arch Surg"},{"key":"9421_CR198","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1080\/0886022X.2016.1202731","volume":"38","author":"M Yang","year":"2016","unstructured":"Yang M, et al. Factors predictive of critical value of hypocalcemia after total parathyroidectomy without autotransplantation in patients with secondary hyperparathyroidism. Ren Fail. 2016;38:1224\u20137.","journal-title":"Ren Fail"},{"key":"9421_CR199","doi-asserted-by":"crossref","first-page":"26841","DOI":"10.1038\/srep26841","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang L, et al. Diagnostic accuracy study of intraoperative and perioperative serum intact PTH level for successful parathyroidectomy in 501 secondary hyperparathyroidism patients. Sci Rep. 2016;6:26841.","journal-title":"Sci Rep."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-017-9421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-017-9421-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-017-9421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T20:49:37Z","timestamp":1750193377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-017-9421-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":199,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9421"],"URL":"https:\/\/doi.org\/10.1007\/s11154-017-9421-4","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}